Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) have received a consensus rating of “Moderate Buy” from analysts, according to a recent report by MarketBeat. The assessment is based on evaluations from six analysts currently covering the stock. Among them, one analyst has issued a sell rating, while four have assigned buy ratings, and one has given a strong buy rating. The average target price for the stock over the next 12 months stands at $19.00.
Analysts have provided several updates regarding Artiva in recent weeks. On October 17, 2024, Wedbush raised its price target from $18.00 to $23.00 and designated the stock as “outperform.” Similarly, Needham & Company LLC reaffirmed a “buy” rating with an $18.00 target price on the same day. In contrast, Weiss Ratings maintained a “sell” rating with a grade of D- in a report dated January 27, 2024. Additionally, HC Wainwright increased its price target from $12.00 to $15.00, emphasizing a “buy” recommendation in a report released on November 12, 2024. Jefferies Financial Group also upgraded Artiva to a “strong buy” in a note issued on November 18, 2024.
Recent Earnings Report and Future Projections
Artiva Biotherapeutics recently disclosed its earnings results for the last quarter on November 12, 2024. The company reported earnings per share of ($0.88), surpassing the consensus estimate of ($0.92) by $0.04. Analysts forecast that Artiva will report an earnings per share of ($4.95) for the current fiscal year, reflecting the ongoing challenges within its operational framework.
Institutional investors have been active in adjusting their holdings in Artiva recently. Citadel Advisors LLC significantly increased its stake in the company by 419.3% during the third quarter, acquiring a total of 798,397 shares valued at approximately $2,291,000. BNP Paribas Financial Markets also expanded its investment by 14,463.5%, now holding 118,547 shares valued at $340,000, after purchasing an additional 117,733 shares. Other notable transactions include new positions by Marshall Wace LLP valued at $79,000, and Jane Street Group LLC, which acquired shares worth $67,000 in the second quarter.
About Artiva Biotherapeutics
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing allogeneic “off-the-shelf” cell therapies aimed at treating cancer. The company’s innovative platform utilizes natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities. This approach aims to deliver effective anti-tumor activity while overcoming the safety and logistical challenges associated with traditional patient-derived (autologous) therapies. Artiva’s pipeline includes several promising product candidates targeting both hematologic malignancies and solid tumors.
For further updates and insights regarding Artiva Biotherapeutics and related companies, interested parties can subscribe to MarketBeat.com for a daily summary of the latest news and analyst ratings.
